Sara DuMond

About Sara DuMond

Sara DuMond, MD, FAAP, 52, is an independent director of United Bankshares, Inc. appointed effective October 21, 2024. She is a practicing pediatrician and founder/CEO of Pediatric Housecalls, PLLC; she earned a BS in physical therapy and an MD from West Virginia University (Alpha Omega Alpha), and completed a pediatrics residency at Carolinas Medical Center . The Governance & Nominating Committee determined she is independent under NASDAQ and SEC rules .

Past Roles

External Roles

Board Governance

• Independence: Determined independent; affirmed in 2025 proxy .
• Committee assignments: As of appointment, not yet assigned to any committees, and not listed on Executive, Audit, Compensation & Human Capital, Risk, or Governance & Nominating Committees in the 2025 proxy .
• Attendance and engagement: In 2024, each incumbent director attended ≥75% of Board and committee meetings; all 14 incumbent directors attended the 2024 annual meeting (DuMond joined in Oct 2024) .
• Board structure context: Lead Independent Director is P. Clinton Winter; independent directors met in executive session twice in 2024 .
• Risk oversight: Board-level Risk Committee oversees enterprise risk across nine categories; all risk-related committees are fully independent .

Fixed Compensation

• Program design: Directors are paid via annual cash retainers and equity awards, with Compensation & Human Capital Committee benchmarking director compensation to a peer group and recommending changes; compensation details are presented annually in the proxy .
• Policy limit: Non-employee director compensation (cash plus equity grant-date value) is capped at $500,000 per calendar year, with permitted exceptions for special/new committees (recipient cannot participate in awarding decision) .
• 2025 director equity grant (DuMond): Received an equity award of 1,904 shares of common stock (Form 4 “A–Award” at $0 grant price) on February 20, 2025 (post-appointment) .

Performance Compensation

• Not disclosed/applicable: United’s non-employee director compensation uses retainers and time-based equity; no performance metrics (e.g., TSR or ROAA targets) are disclosed for director pay .

Other Directorships & Interlocks

• Public company boards: None disclosed for DuMond .
• Related-party/transactions: Upon appointment, company disclosed no Item 404(a) related-party transactions; no selection arrangements; she is compensated per standard non-employee director arrangements .

Expertise & Qualifications

• Clinical leadership and community health advocacy; Fellow of the AAP; advisory roles on evidence-based child health boards; advanced medical training and practice management experience .
• Diversity and board refreshment: One of five independent directors added since 2020, contributing to board refreshment objectives .

Equity Ownership

• Stock ownership guideline: Outside directors must beneficially own at least 5,000 shares; hedging is prohibited; pledging is prohibited (grandfathered exceptions; aggregate pledged shares by Board/NEOs 0.15% of shares outstanding) .
• Beneficial ownership: Her 2025 proxy entry shows 2,454 shares as of March 3, 2025, with post-record-date purchase noted; less than 1% ownership overall .
• Compliance: She met the 5,000-share guideline following her March 24, 2025 open-market purchase .

Equity transactions and holdings detail:

Governance Assessment

• Alignment signals: Independent status, compliance with stock ownership guideline (≥5,000 shares), and a personal open-market purchase (2,600 shares) in March 2025 support ownership alignment and investor confidence .
• Conflicts: No related-party transactions at appointment; no pledging by DuMond disclosed; company policies prohibit hedging/pledging (with limited grandfathering) .
• Influence/engagement: Not assigned to any Board committee as of the 2025 proxy; while common for newly appointed directors, lack of committee placement limits direct oversight responsibilities at present .
• Shareholder feedback context: Say‑on‑pay for executive compensation received strong support (97.58% approval in 2024); 2025 annual meeting approved the 2025 Equity Incentive Plan and re‑elected all nominees, including DuMond .

Related Party Transactions (Conflict checks)

• Policy and oversight: Audit Committee pre-approves and monitors related-party transactions; banking relationships with directors are on market terms; specific related-party transactions disclosed for other directors, not for DuMond .
• No Item 404(a) transactions for DuMond at appointment .

Say‑on‑Pay & Shareholder Feedback

• 2024 advisory vote on NEO compensation: 97.58% approval; Board continues annual say‑on‑pay .
• 2025 annual meeting: Shareholders ratified auditor, approved say‑on‑pay and the 2025 Equity Incentive Plan; all 15 director nominees elected (including DuMond) .

Director Compensation Notes

• Design and benchmarking: Compensation & Human Capital Committee reviews director compensation against peers and recommends adjustments; directors are paid a mix of cash retainers and equity awards; annual cap of $500,000 value for non-employee directors .
• Individual grant record: DuMond received a 1,904-share award on Feb 20, 2025; time-based equity consistent with typical director programs .

Independence, Attendance, and Engagement Summary

• Independence: Yes (per Governance & Nominating Committee determination) .
• Board attendance: Incumbent directors (including those serving during 2024) attended ≥75% of meetings; all incumbents attended the 2024 annual meeting .
• Executive sessions: Independent directors met twice in 2024 .